David Hirsch

David J.
Hirsch is the founder of Longitude Capital Management Co LLC, founded in 2006, where the title held is Venture Partner & Managing Director.
Former jobs include Chief Executive Officer & Director at Alpha-9 Oncology, Inc. from 2022 to 2025; Director at Collegium Pharmaceutical, Inc. from 2012 to 2020; Independent Director at Tricida, Inc. from 2016 to 2023; Director at Helomics Corp.; Director at Predictive Oncology, Inc. from 2009 to 2013; Director at Civitas Therapeutics, Inc. from 2011 to 2014; Director at Velicept Therapeutics, Inc. from 2015 to 2020; Independent Director at Poseida Therapeutics, Inc. from 2018 to 2022; Director at Zavante Therapeutics, Inc. from 2015 to 2018; Director at Inflazome Ltd. from 2018 to 2020; Director at Amunix Pharmaceuticals, Inc. from 2020 to 2022; Independent Director at Molecular Templates, Inc. from 2017 to 2023; Independent Director at Rapid Micro Biosystems, Inc. from 2013 to 2024; Vice President at Pequot Capital Management, Inc. from 2005 to 2006; Engagement Manager at McKinsey & Co., Inc. from 2001 to 2004; Vice President at FirstMark Capital LLC from 2005 to 2006.
Education includes a doctorate from Massachusetts Institute of Technology conferred in 2001, an undergraduate degree from The Johns Hopkins University conferred in 2001, and a doctorate from Harvard Medical School conferred in 2001.